

29 January 2026

The Honorable Susan Donovan Chair, House Committee on Health & Human Services
State House, 82 Smith Street Providence, RI 02903

RE: Support for H7075 and H7188

Dear Chair Donovan and members of the Committee:

I am writing to express my firm support for House Bill No. 7075 and House Bill No. 7188. These pieces of legislation are vital steps toward alleviating the unsustainable financial burden placed on Rhode Islanders who depend on life-saving diabetes supplies.

As a professional working within the healthcare landscape, I see the daily reality of the "cost-of-care" crisis. The rising prices of glucose monitors, insulin delivery systems, and continuous glucose monitoring (CGM) devices have created a landscape where essential medicine is often treated as a luxury. When patients are forced to ration their supplies or skip doses due to financial constraints, we aren't just looking at a budgetary issue—we are looking at a public health emergency.

Reliable access to these tools is the cornerstone of effective diabetes management. When patients can afford to follow their prescribed treatment plans, the results are measurable: better glycemic control, fewer emergency room visits, and a significant reduction in long-term complications such as kidney failure and cardiovascular disease. By passing these bills, the state can help shift the focus from reactive, expensive emergency care to proactive, affordable maintenance.

House Bill No. 7075, the Matt Federico Diabetic Safety Act, is a particularly critical component of this effort. Matt's passing in 2025 serves as a sobering reminder of the stakes involved with Type 1 diabetes. This bill's focus on providing coverage for non-reconstituted glucagon is a common-sense solution that ensures life-saving intervention is simple and accessible during a crisis. It is a necessary protection that honors his memory by preventing similar future tragedies.

By lowering out-of-pocket costs, H7075 and H7188 empower Rhode Islanders to take control of their health. From both a clinical and an economic perspective, the benefits of improved adherence and reduced hospitalizations are undeniable.

I respectfully urge the Committee to support the passage of these bills to ensure a healthier future for our community. Thank you for your time and your dedication to the health and well-being of our state.

Sincerely,

Matthew Brazier PharmD, CDOE

Clinical Pharmacist, Diabetes Care Specialist

Astrana Health-RI

Johnston, Rhode Island